---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-002682"
form_type: "8-K"
ticker: "RLAY"
cik: "0001812364"
company_name: "Relay Therapeutics, Inc."
filed_at: "2024-01-08T23:59:59+00:00"
generated_at: "2026-06-07T02:31:06.697756+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Relay Therapeutics raises $30M in PIPE with Nextech; proceeds for RLY-2608 development

## Summary
- 2.5M shares sold at $12.00 each (premium to Jan 5 close); gross proceeds ~$30M.
- PIPE expected to close Jan 10, 2024; Nextech Crossover I SCP is the investor.
- Proceeds to advance RLY-2608 toward registrational trial(s) and preclinical pipeline.
- Company plans to disclose at least one new Dynamo platform program later in 2024.
- Resale registration statement to be filed within 15 business days.

## SEC filing metadata
- accession: 0000950170-24-002682
- form_type: 8-K
- ticker: RLAY
- cik: 0001812364
- company_name: Relay Therapeutics, Inc.
- filed_at: 2024-01-08T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 1.01, 3.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1812364/000095017024002682/0000950170-24-002682-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1812364/000095017024002682/rlay-20240108.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-002682
- JSON: https://secwatch.observer/filing/0000950170-24-002682.json
- Plain text: https://secwatch.observer/filing/0000950170-24-002682.txt

## Key facts
- Material Agreements
  Relay Therapeutics, Inc. entered into securities purchase agreement with Nextech Crossover I SCP valued at 2,500,000 shares at $12.00 per share for aggregate gross proceeds of approximately $30 million (effective 2024-01-08).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: Nextech Crossover I SCP
  - Value: 2,500,000 shares at $12.00 per share for aggregate gross proceeds of approximately $30 million
  - Effective: 2024-01-08
  source text: On January 8, 2024, Relay Therapeutics, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with Nextech Crossover I SCP (the “Purchaser”), for the private placement (the “Private Placement”) of 2,500,000 shares (the “PIPE Shares”) of the Company’s common stock, $0.001 par value per share (the “Common Stock”), at $12.00 per share.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1812364/000095017024002682/0000950170-24-002682-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.